Pulmonary Medicine Trials

Trials

A Multicenter, Randomized, Double[1]Blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients with Severe Eosinophilic Asthma (DOMINICA)

The study purpose is to learn more about benralizumab (the drug that will be tested in this study) to find out if it may result in an improvement of severe eosinophilic asthma and associated health problems in children.

Sponsor: AstraZeneca AB
NCT05692180 - IRB#2022-174
 
Learn More
 
 
 

Patient reported outcomes in patients with nontuberculous mycobacterial pulmonary disease

The purpose of the study is to learn more about how NTM pulmonary disease symptoms change over time. We are hoping to find out how well certain surveys predict sputum culture results and changes in your cough symptoms

IRB # 2024-027
 
 
 

Phase 2 Study of the Efficacy and Safety of ORC-13661 for the Prevention of Drug-Induced Hearing Loss in Patients Receiving Intravenous Amikacin Therapy for Pulmonary Non-Tuberculous Mycobacterium Disease

IRB # 2024-101
 
Learn More
 
 
 

A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Ensifentrine in Subjects with Non-Cystic Fibrosis Bronchiectasis

IRB # 2024-135
 
Learn More
 
 
 

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101 (Clofazimine Inhalation Suspension) When Added to Guideline-Based Therapy in Participants with Pulmonary Nontuberculous Mycobacterial Infection (Part A) Followed by an Open-Label Extension (Part B)

IRB # 2024-165
 
Learn More
 
 
 

A Phase IIb, Multicentre, Double-blind, Placebo-controlled Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adult Participants With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids (UMBRIEL)

IRB #2025-023
 
Learn More
 
 
 

A Randomized, Double-blind, Multicenter, Parallel-group, Phase IIIb 52 Week Study Evaluating the Efficacy and Safety of PT027 Compared with PT007 Administered As Needed in Participants 12 to < 18 Years of Age with Asthma (ACADIA)

IRB # 2024-190
 
Learn More
 
 
 

Multicenter randomized pragmatic clinical trial comparing two-versus three-antibiotic therapy for pulmonary Mycobacterium avium complex disease

The purpose of this study is to compare the effectiveness and tolerability of a 2-study drug treatment regimen and a 3-study drug treatment regimen in subjects who have recently been diagnosed with pulmonary (lung) disease caused by Mycobacterium avium complex (MAC).

Sponsor: PCORI
IRB#: 1084

Learn More
 
 
 

Bronchiectasis Registry

The purpose of the program is to identify a group of people who are interested in receiving information about research studies focused on bronchiectasis and/or non-tuberculosis mycobacteria (NTM) and possibly participating in these research studies.

Sponsor: COPD Foundation
IRB#: 872

Learn More

 
 
 

CF Registry

The goal of the Patient Registry is to collect data on individuals with cystic fibrosis (CF) to better understand the illness and ultimately improve the care and survival of those with CF.

Sponsor: CFF
IRB#: 678

Learn More

 
 
 

Development of a nontuculous mycobacterial pulmonary disease symptom scale

Development of a nontuberculous mycobacterial pulmonary disease symptom scale

Sponsor: FDA
IRB#: 2022-011

Learn More

 

 


BRONCH Study

BRONCH Study (Bronchiectasis Results Of Natural Clinical History)

Sponsor: UTHSCT
IRB#: 1116